The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: AstraZeneca And Glaxo Give Markets Vaccine Lift

Wed, 03rd Feb 2021 12:03

(Alliance News) - Stock prices in London continued to move higher at midday on Wednesday with sentiment supported by positive news on the progress of coronavirus vaccines.

The FTSE 100 index of large-caps was up 8.46 points, or 0.1%, at 6,525.11. The mid-cap FTSE 250 index was up 72.05 points, or 0.3%, at 20,762.26. The AIM All-Share index was up 0.5% at 1,195.77.

The Cboe UK 100 index was up 0.8% at 649.34. The Cboe 250 was up 0.3% at 18,303.31 and the Cboe Small Companies up 0.6% at 12,301.54.

In mainland Europe, the CAC 40 in Paris was up 0.4% while the DAX 30 in Frankfurt was up 1.4%.

UK drugmaker GlaxoSmithKline and German biopharmaceutical company CureVac announced a new EUR150 million collaboration to jointly develop next-generation mRNA vaccines for Covid-19, with the potential for a "multi-valent approach" to address multiple emerging variants in one vaccine.

Under the terms of the collaboration agreement, Glaxo will have exclusive rights to develop, manufacture, and commercialise the vaccine in all countries with the exception of Germany, Austria and Switzerland. It also will be the marketing authorisation holder for all countries other than Switzerland. Glaxo will make an upfront payment to CureVac of EUR75 million and a further milestone payment of EUR75 million, conditional on the achievement of specific milestones.

Further, Glaxo will also support the manufacture of up to 100 million doses of CureVac's first generation Covid-19 vaccine candidate CVnCoV in 2021. The stock was up 0.3%.

Glaxo also reported its 2020 results at midday. Sales totalled GBP34 billion, up 1% at reported currency rates and 3% at constant rates, while adjusted earnings per share were 115.9 pence, down 6% and 4%, respectively. Glaxo said this was in line with its prior guidance.

In more positive news on the vaccine front, the jab developed by AstraZeneca and the University of Oxford offers protection of 76% up to 12 weeks after a single dose and may reduce transmission by 67%, according to a new study.

After the second dose, vaccine efficacy from two standard doses is 82.4% with the three-month interval being used in the UK, researchers from the University of Oxford say. The data from the study, which has not yet been peer reviewed, supports the four to 12-week prime-boost dosing interval that many global regulators have recommended.

Analyses of positive coronavirus swabs in the UK population suggest the vaccine may have a substantial effect on transmission of the virus, with a 67% reduction in positive swabs among those vaccinated with the Oxford/AstraZeneca jab.

IG Group's Josh Mahony said: "This week sees a return to more normalised drivers of sentiment, with US stimulus, vaccinations, and the prospect of an economic recovery back at the forefront. News that the AstraZeneca vaccine appears to slow the transmission of the virus has been heralded as a significant breakthrough, with many fearing that it may simply lessen the chance of a deadly infection rather than completely stopping patients catching the virus at all.

"With the UK being so reliant upon the AstraZeneca vaccine, any good news for that particular jab has substantial consequences for the reopening prospects in this country."

In the FTSE 100, Vodafone was the best performer, up 4.7%, after the telecommunications firm said it returned to organic service revenue growth in its third-quarter, helped by a much stronger showing in Germany.

Total revenue in the quarter ended December 31 fell 4.7% to EUR11.20 billion from EUR11.75 billion a year earlier. The organic figure - which strips out the effects M&A activity and currency movements - was 0.4%.

Vodafone generates the bulk of its cash from service revenue, which includes monthly access charges, airtime usage and roaming. In the third quarter ended December, service revenue rose 0.4% on an organic basis. The organic service revenue figure is one that is closely eyed by analysts.

In Germany alone, service revenue rose 1.0% year-on-year on both an organic and reported basis to EUR2.91 billion.

Aviva was up 4.4% after Morgan Stanley upgraded the blue-chip insurer to Overweight from Equal Weight.

Taylor Wimpey and Persimmon were up 2.0% and 1.8% respectively after Barclays upgraded both UK housebuilders to Overweight from Equal Weight.

Elsewhere, shares in Dr Martens were trading at 449.55p, up 21% from the initial public offering price of 370p. The iconic boot maker said its entire share capital has begun trading on London's Main Market on Wednesday, with a market value of around GBP4.5 billion. This puts Dr Martens easily in contention for a spot in the FTSE 250 index of mid-caps.

The pound was quoted at USD1.3642 on Wednesday at midday, flat from USD1.3644 at the London equities close Tuesday, but retreating from an intraday high of USD1.3684 after disappointing UK economic data.

UK services sector activity fell sharply in January due to stringent lockdown measures, but optimism improved on hopes for a swift rollout of Covid-19 vaccines, IHS Markit said.

The IHS Markit/CIPS UK services purchasing managers' index print registered 39.5 points in January, down sharply from 49.4 in December and indicated the fastest reduction in business activity for eight months.

The latest reading remained well below the 50.0 mark, which separates expansion from contraction, but beat the market forecast, cited by FXStreet, of 38.8.

In addition, the seasonally adjusted UK composite output index registered 41.2 in January, down from 50.4 in December and back below the crucial 50.0 no-change threshold.

The euro stood at USD1.2021 at midday, down from USD1.2029 late Tuesday, after PMI data from the continent.

Business sector activity in the eurozone worsened in January as lockdown restrictions hit the services industry, the latest figures from Markit showed.

The Markit eurozone services purchasing managers' index reading was 45.4 points in January from 46.4 in December. The latest figure remained well below the 50.0 neutral mark which separates expansion from contraction, but beat the market forecast, cited by FXStreet, of 45.0. Markit said January's reading marked the fifth successive month in which the index has posted a reading below the 50.0 no-change mark.

The eurozone composite PMI score fell to 47.8 points in January from 49.1 in December.

Against the yen, the dollar was trading at JPY105.05, unchanged from late Tuesday.

Brent oil was quoted at USD58.00 a barrel Wednesday midday, up from USD57.58 at the London market close Tuesday. Gold was trading at USD1,835.65 an ounce, a touch lower from USD1,837.20 late Tuesday.

US stock market futures were pointed to a higher open as earnings season continues with fourth-quarter earnings due from online auction site eBay and payments processor PayPal.

The Dow Jones Industrial Average was called up 0.1%, the S&P 500 up 0.4% and Nasdaq Composite up 0.7%.

Shares in Amazon.com will be in focus after the e-commerce company late Tuesday said founder Jeff Bezos will stand aside later this year as chief executive of the firm he built from a startup into one of the world's most valuable entities.

Bezos founded Amazon in his garage in 1994 and went on to grow it into a colossus that dominates online retail, with operations in streaming music and television, groceries, cloud computing, robotics, artificial intelligence and more. His other businesses include the Washington Post newspaper and the private space firm Blue Origin.

The world's richest person based on his Amazon stake, Bezos said he will transition to the role of executive chair in the third quarter, handing over the CEO role to Andy Jassy, who heads Amazon Web Services. The stock is up 0.2% in pre-market trade.

Alphabet shares were up 6.9% in pre-market trade after the Google parent late Tuesday said its quarterly earnings surged at the end of last year as its digital advertising business thrived.

Meanwhile, shares in GameStop were up just 1.4% in pre-market activity, after the video-game retailer dropped by 60% on Tuesday. GameStop over the past week has been the subject of a battle of wills between a group of retail investors and institution short sellers.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.